Tony Adcock is Executive Chairman of Agri-Tech company Food, Fibre & Land International Group Pty Ltd (FFLI) a group that grows broadacre industrial hemp for the Building and Construction industry, Food and Beverage industry, Cosmeceutical, Aromatherapy and Aromachology industries. In addition, FFLI has business in the land reclamation and mine rehabilitation industry. FFLI is an advocate of contemporising the federal legislation of CBD in the nutrition, health and well- being industries to allow economic opportunities for Australia.
Dr Katrina Green is a medical science lecturer in the School of Medicine, University of Wollongong and a scientist at the Centre for Translational Neuroscience, Illawarra Health and Medical Research Institute. Dr Green's research aims to improve the pharmacological treatment of mental illness and to promote healthy aging, with a particular interest in exploring the potential of cannabinoids as novel therapeutics. Dr Green leads a research team that were the first to discover the therapeutic benefits of cannabidiol (CBD) on cognition (learning and memory) in a rodent model of schizophrenia. These findings are particularly important as cognitive impairment in schizophrenia is largely untreatable with current antipsychotic medications.
Rhys is a recognized thought leader in the Australian medicinal cannabis industry. He has previously worked as a freelance commercial consultant and as Senior Project Officer at the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics. Rhys was the lead author on Australia’s first policy white paper on medicinal cannabis. As Principal Consultant at FreshLeaf Analytics, Rhys leads the FreshLeaf team and is responsible for business development and project delivery.
Dr. Adele Hosseini is Chief Scientific Officer at Bod Australia. She has over 18 years’ experience leading the delivery of successful clinical trials including first in human pharmaceuticals and medical devices. She is a pioneer in the Australian medicinal cannabis industry-leading Bod Australia’s Scientific Advisory Board and research program. Over the last three years Dr. Hosseini has developed a deep understanding of medicinal cannabis and continues to development of new strategic direction and development of clinical trials and programs for pharmaceutical cannabis for multiple therapeutic indications for public health benefit.
William Muecke is a co-founding managing member of Artemis Growth Partners LLC, an impact-oriented private equity platform 100% dedicated to investing in the cannabis industry on a worldwide basis. Artemis Growth Partners oversees US $150+ million in discretionary assets under management (AUM) invested in the global cannabis supply chain, including branded products, distributors, value-added service providers, ancillary operators, and science-driven research and development platforms.
Ion Arocena is the Managing Director of ASEBIO, the Spanish biotech industry association. He is a specialist in the evaluation of projects, patents and spin-offs of biotechnology. Since 2009, he teaches Biotechnology Start-ups Financing classes at CESIF (Centro de Estudios Superiores de la Industria Farmacéutica).
Camilo is a Senior Investment Advisor for Procolombia, a government agency in charge of promoting Colombian non-traditional exports, international tourism and foreign investment to Colombia. Before Procolombia, Camilo was Chief Financial Officer (CFO) and Chairman of the Board of Directors at GreenFuel, a biofuels company in Spain and previously he worked as Head of International Commodity Trade Operations and Sustainability and as a Financial Advisor and Lead Mutual Fund Trader.
Kingsley has worked in the financial and investment services industry over the last 25 years, spending 10 years at two large investment banks as a research analyst focused on company analysis, portfolio construction, risk mitigation and institutional sales. As a founding partner of London based Chrystal Capital Partners, he has spent the past 15 years advising companies on raising over US$1.5bn of capital across over 100+ public and private transactions. Over the past four years he has led multiple cannabis investments raising over US$200m in capital from Chrystal’s network of global family offices for a number of different cannabis focused companies. Chrystal Capital is now launching a US$200m cannabis fund called Verdite Capital Fund I to invest across multiple verticals, geographies and stages in the global cannabis industry.
During her 20 years of experience in the life science industry, Hélène has been involved in the research and development, partnering and commercialization of medicines around the world, from Bayer and beyond. Now based in Paris, Hélène is the managing director of Aurora France, a subsidiary of Aurora Europe. In her role, she is in charge of building a strategy for establishing Aurora’s role in the emerging French market, in particular through dialogue with public and private institutions involved in health and market access. Hélène holds a degree in Biochemistry from the University of Montreal and an executive MBA from the University of Quebec in Montreal.
Daniel Mediavilla holds a degree in Audiovisual Communication by the University of Navarra and is one of the founders of Materia, the Science and Technology news web which currently conforms the Science section of El País. Previously, Daniel worked as advisor to the Secretary of State for Research, Felipe Pétriz, in the Ministry of Science and Innovation and in Science Communication for the newspapers ABC and Público.
Andrew is an experienced market commentator helping businesses to get in front of the right investors at the right time with the right message. Andrew has 10 years on-screen experience presenting with the likes of Thompson Reuters, Sky News and ITV. He is an expert on growth stocks – analysing and reporting on global markets, derivatives, equities and commodities.
Luís Mendão concluded his studies in biochemistry in 1983 at the University Pierre et Marie Curie, in Paris. Luís Mendão is currently the Chair of the Board of GAT - Treatment Activist Group, an NGO founded in 2001, focusing on prevention, early diagnosis, treatment and care of HIV/AIDS, viral hepatitis while working with key populations. He is also the founder and on the Board of Directors of the Anti-Prohibitionist Association (SOMA-APA). Currently, he co-chairs the Civil Society Forum on HIV/AIDS at the European Commission and he’s Chair of the European AIDS Treatment Group (EATG). Luís Mendão also integrates to the Steering Committee of the HIVPORTUGAL initiative. In the last ten years, he has been community consultant of the Regional Office of the World Health Organization Europe (WHO Europe), EMCDDA and ECDC. Luís Mendão was diagnosed with HIV and HCV in 1996.
José Luis Martin is a Partner at the law firm Baker Tilly in Spain. José Luis holds 10+ years’ experience in cross-border transactions, M&A, commercial contracts and corporate law. He personally handled the proceedings with the Spanish regulator that led to the first ever cannabis license in Spain.
Yona Cymerman is an entrepreneur and co-founder of Can Innovations, a company focused on introducing innovation to the global cannabis market. The company is now establishing an international innovation accelerator for cannabis related technologies, in conjunction with global names in cannabis and intersecting industries. Prior to her role at Can Innovations, Yona ran her own marketing strategy firm, held the role of VP Strategic Marketing at Ruder Finn and was an adjunct faculty member at the Interdisciplinary Center in Herzliya, Israel.
The world’s leading provider of cannabis intelligence with a blue-chip, cross-industry client base Prohibition Partners was founded in 2017 with a mission to open up the international cannabis industry through reliable data and intelligence.
Within two years Prohibition Partners has become the world’s leading provider of market intelligence and strategic consultancy for this emerging frontier. It is the only company with such widespread global coverage. The consultancy team works with investors, operators and regulators to identify and materialise opportunities across multiple jurisdictions.
MGC Pharmaceuticals Ltd (ASX: MXC, OTCQB: MGCLF) is a European based bio-pharma company supplying phytocannabinoid derived medicines to patients globally. The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia.